Autori: Cho Byoung Chul
| Naslov | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 (Article) |
| Autori | Cho Byoung Chul ... Zaric Bojan |
| Info | JOURNAL OF CLINICAL ONCOLOGY, (2023), vol. 41 br. 26, str. 4208-+ |
| Projekat | The authors would like to thank all the patients who participated in this study and their families and caregivers. The authors would also like to thank the physicians and nurses who cared for the patients and the staff at the clinical sites. |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829) (Meeting Abstract) |
| Autori | Cho Byoung Chul ... Zaric Bojan |
| Info | ANNALS OF ONCOLOGY, (2022), vol. 38 br. 9, Suppl. 9, str. S1560-S1560 |
| Projekat | Yuhan Corporation |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study (Article) |
| Autori | Cho Byoung Chul ... Secen Nevena M ... (broj koautora 19) |
| Info | LANCET ONCOLOGY, (2022), vol. 23 br. 6, str. 781-792 |
| Projekat | Genentech; F Hoffmann-La Roche |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science Scopus |
